PMID- 16077903
OWN - NLM
STAT- MEDLINE
DCOM- 20051205
LR  - 20190513
IS  - 1672-9145 (Print)
IS  - 1672-9145 (Linking)
VI  - 37
IP  - 8
DP  - 2005 Aug
TI  - Silencing of Bcl-XL expression in human MGC-803 gastric cancer cells by siRNA.
PG  - 555-60
AB  - To investigate the inhibitory effect of the Bcl-XL small interfering RNA (siRNA) 
      on Bcl-XL gene expression in the human gastric cancer cell line MGC-803, green 
      fluorescent protein (GFP) siRNA was constructed and transfected into MGC-803 
      cells, together with GFP expression vector pTrace SV40. GFP expression levels 
      were observed using fluorescence microscopy. Bcl-XL siRNA and negative siRNA were 
      then constructed and stably transfected into MGC-803 cells. RT-PCR and 
      immunofluorescence were used to detect the expression of Bcl-XL. Spontaneous 
      apoptosis was detected by acridine orange (AO) and flow cytometry. Results were 
      as follows: (1) 48 h after GFP expression vector and GFP siRNA co-transfection, 
      the expression level of GFP in the GFP siRNA group was much lower than the 
      negative siRNA group, according to fluorescence microscopy results. The mRNA and 
      protein levels of Bcl-XL in Bcl-XL siRNA stable transfectants were reduced to 
      almost background level compared with negative siRNA transfectants or untreated 
      cells. (2) Changes in nucleus morphology was observed by AO staining nucleic and 
      flow cytometry analysis, which showed that stable Bcl-XL siRNA transfectants have 
      an increased spontaneous apoptosis (21.17%+/-1.26% vs. 1.19%+/-0.18% and 
      1.56%+/-0.15% respectively, P < 0.05 vs. negative siRNA or untreated control). 
      siRNA targeting GFP or Bcl-XL genes can specifically suppress GFP or Bcl-XL 
      expression in MGC-803 cells, and Bcl-XL siRNA can increase spontaneous apoptosis. 
      Bcl-XL siRNA may be a beneficial agent against human gastric adenocarcinoma.
FAU - Lei, Xiao-Yong
AU  - Lei XY
AD  - Institute of Pharmacy and Pharmacology, Nanhua University, Hengyang 421001, 
      China. Lei_xiaoyong@hotmail.com
FAU - Zhong, Miao
AU  - Zhong M
FAU - Feng, Lan-Fang
AU  - Feng LF
FAU - Yan, Chun-Yan
AU  - Yan CY
FAU - Zhu, Bing-Yang
AU  - Zhu BY
FAU - Tang, Sheng-Song
AU  - Tang SS
FAU - Liao, Duan-Fang
AU  - Liao DF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Acta Biochim Biophys Sin (Shanghai)
JT  - Acta biochimica et biophysica Sinica
JID - 101206716
RN  - 0 (BCL2L1 protein, human)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (bcl-X Protein)
SB  - IM
MH  - Adenocarcinoma/genetics/*metabolism/*pathology
MH  - Apoptosis/genetics
MH  - Cell Line, Tumor
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Silencing
MH  - Gene Targeting/methods
MH  - Genetic Therapy/methods
MH  - Humans
MH  - RNA, Small Interfering/*genetics
MH  - Recombinant Fusion Proteins/metabolism
MH  - Stomach Neoplasms/genetics/*metabolism/*pathology
MH  - Transfection/methods
MH  - bcl-X Protein/*genetics/*metabolism
EDAT- 2005/08/04 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/08/04 09:00
PHST- 2005/08/04 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/08/04 09:00 [entrez]
AID - 10.1111/j.1745-7270.2005.00077.x [doi]
PST - ppublish
SO  - Acta Biochim Biophys Sin (Shanghai). 2005 Aug;37(8):555-60. doi: 
      10.1111/j.1745-7270.2005.00077.x.